Brief: Acer Therapeutics Announces Initiation Of Its Pivotal Phase 3 Discover Trial Of Edsivo (Celiprolol) For The Treatment Of Vascular Ehlers-Danlos Syndrome
27/06/2022 17:46
June 27 (Reuters) - Acer Therapeutics Inc ACER.O :
* ACER THERAPEUTICS ANNOUNCES INITIATION OF ITS PIVOTAL
PHASE 3
DISCOVER TRIAL OF EDSIVO™ (CELIPROLOL) FOR THE TREATMENT OF
VASCULAR EHLERS-DANLOS SYNDROME
* ACER THERAPEUTICS ANNOUNCES INITIATION OF ITS PIVOTAL
PHASE 3
DISCOVER TRIAL OF EDSIVO™ (CELIPROLOL) FOR THE TREATMENT OF
VASCULAR EHLERS-DANLOS SYNDROME
Source text for Eikon: ID:nGNX1Qxcrg
Further company coverage: ACER.O
Recent news on Acer Therapeutics
See all newsBrief: Leading Independent Proxy Advisory Firms Iss And Glass Lewis Recommend Acer Therapeutics Shareholders Vote "For" The Proposed Merger And Related Proposals
U.S. STOCKS ON THE MOVE-UGI, SkyWest, Sage Therapeutics
Acer Therapeutics surges on Zevra buyout deal
Brief: Zevra Therapeutics To Acquire Acer Therapeutics, Expanding Its Rare Disease Portfolio And Adding Commercial Product
Swiss stocks - Factors to watch on August 31